Hashimoto's Thyroiditis
Overview & Epidemiology
- Most common cause of acquired hypothyroidism and thyroid disease in children and adolescents.
- Replaces former designation "simple adolescent goiter".
- Peak incidence during adolescence (11โ15 years); may present as early as first year of life.
- Strong female predominance; Female:Male ratio 4-6:1.
- Prevalence: 1-2% of school-age children and 6-8% of adolescents possess thyroid autoantibodies.
Pathogenesis & Molecular Genetics
- Organ-specific autoimmune disease resulting from combined genetic susceptibility and environmental triggers.
Histopathology
- Thyroid follicular hyperplasia occurs early.
- Progressive infiltration of lymphocytes (T-helper CD4+, cytotoxic CD8+) and plasma cells into thyroid follicles.
- Formation of lymphoid follicles with germinal centers.
- Chronic inflammation progresses to follicular fibrosis, parenchymal destruction, and eventual glandular atrophy.
Autoantibodies & Immune Mechanisms
- Anti-Thyroperoxidase (TPO-Ab): Primary destructive autoantibody. Activates complement cascade; mediates antibody-dependent cell-mediated cytotoxicity.
- Anti-Thyroglobulin (Tg-Ab): Frequently present; lacks direct role in autoimmune glandular destruction.
- TSH Receptor-Blocking Antibodies (TRBAb): Bind to TSH receptor preventing TSH action; induce severe thyroid atrophy; present in 18% of cases with profound hypothyroidism (TSH >20 mU/L).
Genetic Associations
- HLA Haplotypes: HLA-DR4 and HLA-DR5 associated with increased risk of goitrous variant. HLA-DR3 associated with atrophic variant.
- Immunomodulatory Genes: Polymorphisms in CTLA4, PTPN22, and HLA-D3/D4 alleles increase susceptibility, particularly within Autoimmune Polyglandular Syndrome Type 2 (APS-2) cohorts[^aps2].
Clinical Manifestations
Thyroid Gland Characteristics
- Diffuse goiter and growth deceleration represent hallmark classical presentation.
- Gland consistency: Firm, nontender, rubbery.
- Surface texture: Bosselated (pebbly or cobblestone appearance).
- Asymmetric enlargement occasionally occurs; clinically mimics solitary thyroid nodule.
Disease Phases & Functional Status
| Phase | Pathophysiology & Clinical Features |
|---|---|
| Euthyroid Phase | Most common initial presentation. Asymptomatic goiter. Normal FT4 and TSH. Goiter may persist or spontaneously regress. |
| Hashitoxicosis | Transient thyrotoxicosis (1-5% of cases). Caused by inflammatory follicular destruction releasing preformed T4/T3. Lasts up to 60 days. Manifests with tremulousness, sweating, hyperactivity, irritability. Distinguishable from Graves disease by absence of Thyroid-Stimulating Immunoglobulins (TSI), absence of true ophthalmopathy, and low radioiodine uptake. |
| Overt Hypothyroidism | Insidious onset. Clinical signs: Cold intolerance, severe constipation, bradycardia, lethargy, delayed deep tendon reflexes, dry/scaly skin, carotenemia (yellow skin, white sclerae). |
Impact on Growth and Development
- Growth Failure: Slowing of linear growth is frequently the initial, unrecognized clinical manifestation. Severe stunting of linear growth and delayed skeletal maturation (bone age) characterize untreated disease. Weight gain driven primarily by fluid retention (myxedema), not true adiposity.
- Delayed Puberty: Typical in older adolescents with chronic hypothyroidism.
- Van Wyk-Grumbach Syndrome (Pseudoprecocious Puberty): Occurs in ~50% of children with profound, long-standing, untreated hypothyroidism.
- Pathophysiology: Massively elevated TSH (>500 mU/L) cross-reacts with Follicle-Stimulating Hormone (FSH) receptors (specificity spillover) inducing FSH-like effects without Luteinizing Hormone (LH) action.
- Female Features: Early menarche, breast development, large multicystic ovaries, absence of pubic hair, delayed bone age, and galactorrhea (TRH-induced hyperprolactinemia).
- Male Features: Macroorchidism (testicular enlargement) without significant penile growth or virilization.
Comorbid Autoimmune & Syndromic Associations
High risk for concurrent chromosomal abnormalities and other autoimmune endocrinopathies. Annual surveillance for associated disorders is mandatory.
| Category | Associated Conditions & Clinical Notes |
|---|---|
| Chromosomal Disorders | Trisomy 21 (Down syndrome): 30% develop antibodies; 15-20% develop overt hypothyroidism. Turner Syndrome (45,X): 40% develop antibodies; 15-30% acquire hypothyroidism. Klinefelter Syndrome (47,XXY): Increased incidence of generalized autoimmunity. |
| Autoimmune Polyglandular Syndrome Type 1 (APS-1) | Autosomal recessive (AIRE gene mutation). Triad: Hashimoto thyroiditis occurs in ~30% of cases. |
| Autoimmune Polyglandular Syndrome Type 2 (APS-2) | Polygenic inheritance (HLA-DR3/DR4). Features: |
| IPEX Syndrome | X-linked recessive (FOXP3 gene mutation). Features: |
| Isolated Autoimmune Conditions | Type 1 Diabetes Mellitus: ~20% prevalence of TPO-Ab; 5% acquire overt hypothyroidism. Celiac Disease: Occurs in 1% of Hashimoto cases. Others: Vitiligo, Alopecia, Myasthenia gravis, Pernicious anemia, Autoimmune hepatitis. |
Diagnostic Evaluation
Biochemical Testing (Thyroid Function Tests)
Requires age-specific pediatric reference ranges to avoid erroneous over-diagnosis of subclinical disease.
- Euthyroid: Normal TSH, Normal FT4.
- Subclinical Hypothyroidism: Mildly elevated TSH (e.g., 5-10 mU/L), Normal FT4.
- Overt Hypothyroidism: Markedly elevated TSH (>10 mU/L), Low FT4.
- Ancillary Labs in Severe Disease: Hyponatremia, macrocytic anemia, hypercholesterolemia, elevated creatine phosphokinase (CPK).
Autoantibody Markers
- TPO-Ab & Tg-Ab: Testing for both antibodies yields >95% diagnostic sensitivity.
- Clinical Utility limitations: Absolute antibody titers do not correlate with current thyroid function or disease severity. Serial monitoring of autoantibody titers is not clinically recommended after initial diagnosis.
Imaging Modalities
- Ultrasound: Reveals diffusely heterogeneous echotexture; frequently demonstrates increased hyperplastic, benign-appearing cervical lymph nodes. Primary indication: Evaluation of palpable discrete thyroid nodules or marked glandular asymmetry to rule out malignancy.
- Scintigraphy (Radionuclide Scan): Demonstrates patchy, irregular, decreased radioisotope uptake. Rarely indicated for routine diagnosis. Differentiates Hashitoxicosis (low uptake) from Graves disease (high, diffuse uptake).
Management & Pharmacotherapy
Treatment Indications & Strategies
- Euthyroid Goiter: Observation is the standard of care. Suppressive Levothyroxine (L-T4) therapy aimed at shrinking the goiter yields limited benefit, does not alter the underlying autoimmune process, and is generally avoided due to adverse effects of iatrogenic thyrotoxicosis.
- Subclinical Hypothyroidism (TSH 5-10 mU/L): Observation is acceptable; ~35% spontaneously revert to euthyroidism. Treatment indicated if TSH persistently >10 mU/L, progressive thyromegaly occurs, or symptoms develop.
- Overt Hypothyroidism: Prompt initiation of oral Levothyroxine (L-T4).
Levothyroxine (L-T4) Dosing
Dosing requirements decrease with advancing age/weight.
| Age Group | Daily L-T4 Dose Requirement |
|---|---|
| 1 - 3 years | 4 - 6 mcg/kg/day |
| 3 - 10 years | 3 - 5 mcg/kg/day |
| 10 - 16 years | 2 - 4 mcg/kg/day |
High-Yield Pharmacotherapy Precautions
- Pseudotumor Cerebri Risk: In patients presenting with profound, long-standing hypothyroidism, initiating full-dose L-T4 can precipitate intracranial hypertension (pseudotumor cerebri).
- Strategy: Initiate therapy at 1/3 to 1/2 of the conventional calculated dose. Up-titrate gradually to the full replacement dose over 2-4 weeks.
- Acute Myopathy Risk: Rapid correction of chronic hypothyroidism may rarely induce acute myopathy with massive CPK elevation and severe muscle cramps; requires careful monitoring during initial treatment phase.
- Adrenal Crisis Risk: In patients with concurrent Autoimmune Polyglandular Syndrome (APS), unrecognized Addison disease must be excluded before initiating L-T4. Thyroid hormone accelerates cortisol metabolism; L-T4 administration prior to glucocorticoid replacement can precipitate fatal adrenal crisis.
Monitoring & Follow-Up
- Therapeutic Targets: Maintain TSH strictly within the age-specific normal reference range. In children <3 years, maintain FT4 in the upper half of the normal reference range to optimize neurodevelopment.
- Monitoring Frequency: Re-evaluate TSH and FT4 every 4-6 weeks following any dose adjustment. Once stable, monitor every 4-6 months.
- Behavioral Changes: Transient deterioration in schoolwork, poor sleep, restlessness, and short attention span may occur during the first year of therapy as metabolism normalizes; anticipatory guidance for parents is essential.
Prognosis & Long-Term Outcomes
- Spontaneous remission of subclinical disease occurs in up to 35% of cases.
- Euthyroid goiters may persist for years before shrinking.
- Once overt hypothyroidism develops, lifelong L-T4 replacement is typically required.
- Growth Prognosis: Rapid catch-up growth follows treatment initiation. However, in severely delayed diagnoses, premature fusion of epiphyses limits complete catch-up, resulting in permanently compromised final adult height. Ensure serial monitoring of growth velocity and bone age.